unknown by Nuessler, V. et al.
Biomarkers and translational research
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ABSTRACT: Biomarkers have the potential to play important
roles in diagnosis and in the identification of patient populations
that could benefit from targeted therapy. They also serve as mark-
ers of drug efficacy and could be used to monitor treatment effec-
tiveness, drug toxicity, and development of resistance. One
example of a successful biomarker development is represented
by the testing for Her-2/ERB2 over expression. Tissue sampling
is crucial for the definition and validation of new biomarkers. In
general, biomarker and its corresponding assay must be validated
before phase III to be useful in reducing trial size.
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DEVELOPMENT OF BIOMARKERS: WHAT ARE THE SCIENTIFIC
HURDLES?
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For next-generation therapies drug development by chance is
moving toward cancer therapies that are molecularly targeted.
Nevertheless, drug development still relies on the same basic
strategies used for cytotoxic drugs. In the new era of cancer treat-
ment, instead of applying the concept of maximum tolerated
dose (MTD) as does cytotoxic drug therapy, we must think in
terms of the optimal biologically active dose (OBAD) and, perhaps,
the maximum tolerated economic cost. Only administration of
molecularly targeted drugs at OBAD can demonstrate their opti-
mum therapeutic efficacy.
Biomarkers could play important roles in disease diagnosis
and in the identification of patient populations that could benefit
from targeted therapy. They also serve as markers of drug efficacy
and could be used to monitor treatment effectiveness, drug toxic-
ity, and development of resistance. Moreover, some biomarkers
appear to be surrogates for clinical benefit; as such, they have
the potential to serve as endpoints in clinical trials. To use bio-
markers to maximum advantage, several scientific hurdles must
be surmounted. For example, a need exists to differentiate molec-
ular and therapeutic targets, determine which targets to block to
achieve tumour control, overcome resistance mechanisms, and
identify patients who need treatment and are potential
responders.
Many techniques – genomics, proteomics, interactomics,
peptidomics, and degradomics – offer a spectrum of analytical
possibilities. In the early days, procedures involved removing
most proteins, e.g. albumin, prior to analysis. That approach,
unfortunately, eliminates the opportunity to investigate inter-
actomics involving the small peptides bound to large molecules.
To identify potential biomarkers and study their roles in the dis-
ease pathway, it is necessary to look for small molecules in serum
(peptidomics) as well as protein-degradation products (degrado-
mics). Many peptides have excellent cancer signatures. Reverse-
phase protein microarray provides a map of known cell-signalling
proteins.1
Biomarker development should follow different pathways
depending on the stage of drug development. For early stages of
clinical development, biomarkers can identify or confirm molecu-
lar targets, help optimise dose schedules for the anticancer agent,
and might correlate with clinical benefit. Identifying clinically rel-
evant targets is challenging; in numerous examples, the intended
target was found to be irrelevant. As not all molecular targets are
legitimate therapeutic targets, however, biomarkers can provide a
means of determining which target(s), when inhibited, correlate
with tumour control. In the case of some anticancer agents
(e.g. cetuximab, gefitinib, farnesyl transferase inhibitors, and
inhibitors of vascular endothelial growth factor [VEGF]), it appears
that the original molecular target is not the only therapeutic
target.
In the later stages of clinical development, identified markers
could be used to select the patients most likely to respond to the
targeted agent. Any biomarker used as a basis for patient selec-
tion must demonstrate excellent sensitivity and specificity; other-
wise, the risk of not treating patients who might benefit would be
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